Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Empagliflozin for MASLD in T2D
NCT03646292Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pioglitazone, empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Yonsei University. Started Dec 2018; status: completed.
02
Drugs
pioglitazoneempagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT03646292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646292.